Answers are grounded in this paper and cite their sources.
Bovine parainfluenza virus type 3 (BPIV3) contributes to bovine respiratory disease complex, but the role of the interferon-associated host protein N-Myc and STAT interactor (NMI) in BPIV3 infection remains unclear. We evaluated pre-challenge supplementation with bovine NMI (BoNMI) in bovine respiratory-related cells and short-term mouse models. Recombinant TAT-BoNMI was detected in cell-associated samples from bovine bronchial epithelial cells (BBEC) and embryonic bovine tracheal cells (EBTr), with no measurable reduction in viability after short exposure at the selected concentration. BoNMI-treated cells showed lower BPIV3 RNA levels and infectious titers; the titer pattern was not reproduced by TAT-mScarlet. In the BPIV3– Pasteurella multocida type A (PmA) co-challenge model, 2 of 6 untreated mice died during days 0–3, whereas all six BoNMI-treated mice survived. Lung bacterial counts were lower in the treated co-challenge group; histology was assessed qualitatively. BPIV3 V protein exposure was associated with an MG132-sensitive reduction in BoNMI abundance, and BoNMI supplementation was associated with enhanced IFN-β-induced STAT1 phosphorylation. These preliminary findings support further evaluation of BoNMI supplementation in experimental BPIV3 infection. The short-term pre-challenge design and associative signaling findings limit conclusions about therapeutic efficacy and mechanism.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: